Navigation Links
Clinical studies show REMICADE reduces incidence of bowel surgeries in ulcerative colitis patients
Date:10/15/2007

< 0.05).

"These diseases are devastating to patients and their loved ones and we are excited to see more and better therapies become available to ease their suffering," said Richard J. Geswell, President, Crohn's & Colitis Foundation of America.

About the ACT Long-Term Extension

Patients with moderate to severe UC, defined as a baseline Mayo score 6 and 12, who were unresponsive to or intolerant to at least one standard therapy, including corticosteroids, immunosuppressants or 5ASAs, were enrolled in ACT 1 (n=364) or ACT 2 (n=364). The 728 patients were randomized to receive REMICADE 5 mg/kg, REMICADE 10 mg/kg or placebo at weeks 0, 2, 6 and every subsequent 8 weeks through week 22 (ACT 2) or week 46 (ACT 1). Patients were allowed to continue to receive conventional therapy.

Patients who completed treatment through the final infusion visit and who, in the opinion of the investigator, could benefit from continued treatment with REMICADE could enroll in the extension trials. Across multiple sites, one hundred and eighteen (118) patients were entered into the ACT 1 extension and 111 patients were entered into the ACT 2 extension.

During the extension, patients continued to receive the study drug to which they were originally randomized (REMICADE 5 mg/kg, REMICADE 10 mg/kg or placebo) every 8 weeks. Patients in the extension trials were assessed using the Physicians Global Assessment (PGA), which is 1 of 4 measures of disease activity included in the Mayo score. Of the 229 patients who entered the extension, 181 have been followed through one year, and 92 have completed two years. Patients who had responded to placebo also enrolled in

the extension to maintain the blind and continued to receive placebo every 8 weeks.

Overall, REMICADE was generally well tolerated in the long-term extensions, with less than five percent of patients discontinuing therapy due to an adverse event (AE). As previously rep
'/>"/>

Contact: Melissa Katz
215-325-6875
Centocor, Inc.
Source:Eurekalert

Page: 1 2 3 4 5 6

Related biology news :

1. Roche clinical trial registry and results database launched
2. NIAID begins clinical trial of West Nile virus vaccine
3. Compound might defeat African sleeping sickness, clinical trial beginning this month
4. Neurologix announces positive results of gene therapy clinical trial in Parkinsons disease
5. Dalai Lama, top scientists to discuss science & clinical applications of meditation
6. Stem cells electric abilities might help their safe clinical use
7. Clinical trial to test stem cell approach for children with brain injury
8. New malaria vaccine shows promise in early clinical trial
9. Preclinical study of a new brain tumor therapy
10. Tramiprosate (Alzhemed? preclinical results published in Neurobiology of Aging
11. Fatty spheres loaded with siRNA shrink ovarian cancer tumors in preclinical trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014 ... Global Government Biometric Systems Market 2014-2024   Business ... The Global Biometric Systems Market 2014-2024" offers the ... market over the next ten years, alongside potential ... market size forecasts. To view the ...
(Date:7/30/2014)... an across-the-board increase in Impact Factors for its ... Citation Reports (Thomson Reuters, 2014) show that ... Essays in Biochemistry , Biochemical Society Transactions ... increases in their Impact Factors. The journals are ... Portland Press Limited. , 2014 Impact Factors (2013 ...
(Date:7/30/2014)... massive collection of 20-million-year-old amber found in the Dominican ... is yielding fresh insights into ancient tropical insects and ... fully curated, a task that will take many years, ... in the world, the researchers report. , Perhaps ... a pygmy locust, a tiny grasshopper the size of ...
Breaking Biology News(10 mins):Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 2Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 3Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 4Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 5Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 6Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 7Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 8Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 9Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 10Across-the-board Impact Factor increases for Portland Press Limited 2Decades-old amber collection offers new views of a lost world 2
... On a popular children's game participants stand as close ... coaxing cells to be very, very close without actually ... challenges for cell biologists. , Now MIT researchers led ... computer science at the Harvard-MIT Division of Health Sciences ...
... Researchers at Mount Sinai School of Medicine have just ... of the microdomains of leukocytes or white blood cells. ... cells in which receptors and signaling molecules accumulate during ... to view white blood cell subsets and their forming ...
... sugars, a technique developed by University of Michigan analytical ... diagnosis and treatment options. , A growing body of ... to proteins on cancer cell surfaces as accomplices in ... keen to characterize these glycans, but traditional analytical methods ...
Cached Biology News:MIT device draws cells close -- but not too close -- together 2MIT device draws cells close -- but not too close -- together 3New imaging technique tracks traffic patterns of white blood cells 2A sweet step toward new cancer therapies 2
(Date:7/30/2014)... 2014  AtheroNova Inc. (OTCBB: AHRO), a biotech ... compounds to safely regress atherosclerotic plaque and improve ... partner, CardioNova, has accomplished first dosing of subjects ... lead compound, AHRO-001.  This Phase 1b trial will ... safety trial completed in February 2014, in which ...
(Date:7/30/2014)... 30, 2014 NCERC at Southern ... present his findings on corn stover pretreatment methods ... week in Washington, D.C. , “Arun’s selection ... is a testament to the success of our ... “Thanks to the foresight and vision of SIUE ...
(Date:7/30/2014)... July 30, 2014 Vala Sciences ... U.S. Environmental Protection Agency (EPA). This new contract ... toxicity models, including tests designed to assess the ... the formation of connections between neurons (synapses), which ... and synapse formation by environmental pollutants likely contributes ...
(Date:7/30/2014)... July 30, 2014 Immunology ... leading Immunologists, Principle Investigators, scientists in the field, ... Malemud, Professor at Case Western Reserve University School ... keynote address on “The effects of recombinant ... of matrix metalloproteinase-9”. Arya Biragyn, a Senior investigator ...
Breaking Biology Technology:AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 2NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 3U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3
... 1, 2012  Receptos Inc. today announced that the company is ... Health Care Conference at noon EST on Wednesday, March 7, ... Faheem Hasnain, president and chief executive officer, will provide an ... development programs. "This is an exciting time ...
... 2012 Unigene Laboratories, Inc. (OTCBB: UGNE), a leader ... therapeutics announced today that the Company,s senior management team ... on Thursday, March 8, 2012 at 11 a.m. ET ... Interested participants and investors may access ...
... Enox Biopharma, Inc. (VANCOUVER, BC.) CEO, John C. Rewcastle, Ph.D., ... Thursday, March 1 at 10:35 AM EST. The conference is ... The IN360 is the newest iteration of the ... medical device technology forum and networking meeting. The foundation of ...
Cached Biology Technology:Receptos to Present at the Cowen and Company 32nd Annual Health Care Conference 2Unigene to Announce Fourth Quarter and Full-Year 2011 Financial Results on March 8, 2012 2Enox Biopharma, Inc. Will Present at IN360 Investment in Innovation Conference 2
Mouse monoclonal antibody raised against a partial recombinant WDR5. NCBI Entrez Gene ID = WDR5...
... kit is a sample preparation kit for ... removal of detergents, phenolic compounds, salts, and ... dilute samples. The kit procedure involves a ... tissue or cells, plant leaves, E. coli, ...
... is intended for first-time users of the PROTEAN ... includes a protein sample and reagents sufficient to ... 17 cm, ten 11 cm, or sixteen 7 ... precast SDS-PAGE gels and gels stains are not ...
... Immunogen : Fusion protein ... 474-970 of human Mi-2 Formulation: ... NaCl, 0.035% sodium azide, containing ... evaluated by immunoblot on Hela ...
Biology Products: